Exploring the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions – September 29

Live Nationwide CME Webcast!
Tuesday, September 29, 2020
9:00 PM – 10:00 PM (ET)
8:00 PM – 9:00 PM (CT)
7:00 PM – 8:00 PM (MT)
6:00 PM – 7:00 PM (PT)


Join us for this
LIVE Nationwide Interactive CME Webcast!



Until recently, treatment options for severe asthma with an eosinophilic phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome were limited mostly to immunosuppression with oral corticosteroids (OCS) or other systemic agents. An expanding understanding of the pathophysiology of these diseases has led to the identification of newer therapeutic targets and more selective and better tolerated treatments for eosinophil reduction. This interactive webcast will review strategies for recognizing these phenotypes of severe eosinophilic diseases of the lungs and help the clinician better navigate available treatments in order to improve symptoms, lighten the disease burden, and reduce exacerbations and OCS reliance for patients with severe asthma and associated eosinophil-mediated conditions.


This dynamic Practitioner’s EdgeSM webcast will utilize the collective results of an interactive case study simulation completed by participants prior to the program. Upon registration, instructions for the case study simulation will be provided. Faculty members will compile and review the participants’ responses to the simulation during the live webcast, which will serve as a catalyst for discussion and best-practice reinforcement. Interactive polling questions and a 3D animation will also be available during the live program to review treatment of severe asthma and associated eosinophil-mediated conditions.



Bradley E. Chipps, MD
Medical Director
Capital Allergy and Respiratory Disease Center
Sacramento, California



This educational initiative is intended for allergists, pulmonologists, nurse practitioners, physician assistants, and other practitioners who manage patients with asthma and associated eosinophil-mediated conditions.


Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why rarer orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma
  • Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on OCS


Physician Continuing Education


Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In order to receive credit for this activity, the participant must complete the preprogram case study simulation, the pretest and posttest, view the live Webcast, and complete the evaluation form. A statement of credit will be issued only upon submission of a completed activity evaluation form.


There is no fee for this educational activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


Integrity Continuing Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty Disclosures
Bradley E. Chipps, MD
Consultant: AstraZeneca, Boeringer Ingelheim, Genentech, Novartis, Regeneron, Sanofi Genzyme
Honoria (non-CME Services): AstraZeneca, Boeringer Ingelheim, Genentech, Novartis, Regeneron, Sanofi Genzyme

Integrity Continuing Education planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


This CME activity is provided by Integrity Continuing Education.


This activity is supported by an educational grant from GlaxoSmithKline.


Please use link below to access the live webcast on the day of the event.